Blacktrace Holdings Ltd. to in-license PerkinElmer Technology
News Aug 04, 2014
Blacktrace Holdings Limited today announced that it has entered into an agreement with PerkinElmer to license certain microfluidic technology owned by its subsidiary, Caliper Life Sciences, Inc., for a wide range of applications. The Blacktrace group includes a number of well-known brands. Dolomite Microfluidics is a leading solution provider of systems and components such as microfluidic droplet systems, microfluidic chips, pumps and connectors, as well as custom solutions and bespoke product development services. Syrris is a leader in chemistry tools, with its award-winning 4th generation Asia Flow Chemistry System being the most successful flow reactor ever.
The license provides Blacktrace with maximum flexibility as it expands its product ranges to include more microfluidic chips and technology, and develops new innovative platforms that will deliver superior performance to its customers worldwide. PerkinElmer continues to leverage its microfluidics portfolio through licensing collaborations to extend its market reach.
Miniature Testing of Drug Pairs on Tumor BiopsiesNews
Combinations of cancer drugs can be quickly and cheaply tested on tumour cells using a novel device. The research marks the latest advancement in the field of personalised medicine. Using a microfluidic device that fits in the palm of your hand, scientists screened over 1100 treatment conditions on patient tumour cells. In the future, such tests could be used to inform clinicians on safe and effective combinations of cancer treatments.READ MORE
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE